Latest Fludarabine Stories

2010-07-01 17:05:00

WASHINGTON, July 1 /PRNewswire-USNewswire/ -- Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology.

2010-02-18 15:49:00

SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S.

2009-12-05 14:00:00

The methods and outcomes for stem cell transplants are constantly improving as leading experts continue to investigate new approaches for reducing the serious adverse events associated with the procedure.

2009-08-05 10:16:00

SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin hydrochloride injection. IMS data indicates the combined U.S.

2009-05-28 06:30:00

US drug regulators are carefully scrutinizing a new leukemia drug from pharmaceutical giant GlaxoSmithKline PLC and Genmab to determine whether the medication offers patients enough benefit to sanction its approval.

2009-05-11 15:30:00

BRIDGEWATER, N.J., May 11 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that it has acquired from biotechnology company Antisoma plc the U.S. commercial rights to Oforta(TM) (fludarabine phosphate film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug.

2009-01-30 10:00:00

Three New Studies Initiated in Other Oncology Settings LONDON and COPENHAGEN, Denmark, Jan. 30 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the U.S.

2008-12-10 07:30:00

Published in the Journal Blood for the American Society of Hematology Annual Meeting SOMERSET, N.J., Dec.

2008-12-09 07:00:00

Data Showed Campath May Lead to Overall Survival in Patients with Poor Prognostic Factors SAN FRANCISCO, Dec. 9 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc.

2008-12-08 12:59:00

Data from a pivotal trial suggests that ofatumumab has activity in heavily pre-treated patients who have failed standard treatments PHILADELPHIA, Dec.

Word of the Day
  • Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.
The word 'quotha' is an alteration of 'quoth he'.